Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

Hispanic mortality paradox found in RA patients

The so-called “Hispanic survival paradox” has been found to extend to patients with rheumatoid arthritis, whereby Hispanic people with the condition tend have more severe symptoms but equivalent mortality to non-Hispanic White individuals.

19 Dec 2013

Workers and some employers wary of incentives to improve health

The health law allows job-based health plans boosts the rewards for workers who adopt healthier habits.

19 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

Researchers develop potential treatment for atherosclerosis

Researchers at Emory and Georgia Tech have developed a potential treatment for atherosclerosis that targets a master controller of the process.

18 Dec 2013

Potential dual benefits to tackling LUTS progression risk factors

Research shows that several risk factors associated with Type 2 diabetes and cardiovascular disease also predict the progression of storage and voiding lower urinary tract symptoms in men, suggesting that targeting these could have multiple benefits.

16 Dec 2013

Cornell engineers create smartCARD that uses smartphone's camera to read cholesterol level

With a new smartphone device, you can now take an accurate iPhone camera selfie that could save your life - it reads your cholesterol level in about a minute.

16 Dec 2013

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

A Massachusetts General Hospital research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In the Dec. 1 issue of the Journal of Infectious Diseases the investigators report finding that HIV-infected women had a greater prevalence of the type of coronary artery plaque most vulnerable to rupture than did uninfected women.

14 Dec 2013

Children can reap positive health benefits from increased physical activity

Studies conducted by the Appalachian State University Human Performance Laboratory at the NC Research Campus in Kannapolis, N.C., show that when children increase their level of physical activity, they experience positive health benefits quickly.

13 Dec 2013

Texas Children's Heart Center opens Center for Preventive Cardiology

Texas Children's Heart Center is proud to announce the opening of the Center for Preventive Cardiology, which is designed to medically manage the risk factors of acquired heart disease in children. The center is the only one of its kind in Texas that offers multidisciplinary, specialized care for children with these risk factors or who have a strong family history of cardiac disease, elevated cholesterol, high blood pressure or the diagnosis of Kawasaki disease.

13 Dec 2013

Massachusetts residents have broader health insurance coverage, greater access to primary care

In 2006, Massachusetts was on the same brink that the entire nation is on today: the brink of expanding health insurance to cover far more people than before, through government-driven, market-based reform.

13 Dec 2013

Nearly 98% of Massachusetts residents now have Medicaid coverage

Nearly 98 percent of Massachusetts' 400,000 residents now have coverage—either through individual purchase or expanded Medicaid coverage for children and low-income residents. And while the reform was initially met with controversy, it has gained popularity in the past 5 years.

13 Dec 2013

Research suggests connection between adult's height and prevalence of CAC

Minneapolis Heart Institute Foundation research cardiologist Dr. Michael Miedema is the lead author of a paper published by Circulation - Cardiovascular Imaging, a journal of the American Heart Association, that suggests a connection between an adult's height and the prevalence of coronary artery calcium (CAC), a direct marker of plaque in the arteries that feed the heart.

13 Dec 2013

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to researchers at Washington University School of Medicine in St. Louis.

13 Dec 2013

Inflating balloon inside artery after stent placement increases patients' risk of serious complications

Johns Hopkins surgeons say skipping one commonly taken step during a routine procedure to insert a wire mesh stent into a partially blocked carotid artery appears to prevent patients from developing dangerously low blood pressure, an extremely slow heart rate or even a stroke or heart attack.

12 Dec 2013

High cholesterol fuels growth and spread of breast Cancer

Researchers at Duke Medicine conclude that high cholesterol may make breast cancer worse when they found that a byproduct of cholesterol functions like the hormone estrogen, leading to increases in the growth and spread of breast cancer. Studies have previously shown the link between obesity and breast cancer, but the exact cause of the increased risk had not been identified.

11 Dec 2013

COC launches first clinic on London's Harley Street for specialised cancer treatment

Care Oncology Clinic, an independent, private organisation providing oncology treatments, announces today the launch of its first clinic on London's Harley Street. Delivered by leading oncologists and palliative care doctors, the clinic is the first of its kind, specifically set up to offer a specialised cancer treatment by targeting the energy requirements of cancer cells using existing medicines that are already licensed for this purpose, have an acceptable safety profile and are low cost. Designed for patients for whom the standard oncology treatment regime is not available, viable, tolerable or providing benefit, this is a new option for treating these cancer patients.

10 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

Researchers identify central switch by which HDL controls inflammatory response

High-density lipoprotein, known colloquially as "good cholesterol", protects against dangerous deposits in the arteries. An important function of HDL is its anti-inflammatory properties. An international research team at the Institute of Innate Immunity at the University Hospital of Bonn and the LIMES Institute at the University of Bonn has identified a central switch by which HDL controls the inflammatory response. The results are presented in the current issue of "Nature Immunology".

9 Dec 2013

Angioplasty may not provide additional benefits compared to drug therapy for patients with stable CAD

For patients with stable coronary artery disease (CAD) who are not experiencing a heart attack and an abnormal stress test, treatment of their narrowed arteries by the common procedure of angioplasty may not provide additional benefits compared to drug therapy alone.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Cholesterol News and Research

Further Reading

Hispanic mortality paradox found in RA patients

Workers and some employers wary of incentives to improve health

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Researchers develop potential treatment for atherosclerosis

Potential dual benefits to tackling LUTS progression risk factors

Cornell engineers create smartCARD that uses smartphone's camera to read cholesterol level

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

Children can reap positive health benefits from increased physical activity

Texas Children's Heart Center opens Center for Preventive Cardiology

Massachusetts residents have broader health insurance coverage, greater access to primary care

Nearly 98% of Massachusetts residents now have Medicaid coverage

Research suggests connection between adult's height and prevalence of CAC

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Inflating balloon inside artery after stent placement increases patients' risk of serious complications

High cholesterol fuels growth and spread of breast Cancer

COC launches first clinic on London's Harley Street for specialised cancer treatment

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Researchers identify central switch by which HDL controls inflammatory response

Angioplasty may not provide additional benefits compared to drug therapy for patients with stable CAD

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News